Genetic Testing And Diagnostics - USMLE Step 1

SECTION 1

Historical Context & Motivation

The ability to interrogate the human genome at the molecular level represents one of the most transformative advances in modern medicine. Before the advent of genetic testing, clinicians relied almost exclusively on phenotypic observation, family pedigree analysis, and biochemical assays to infer the presence of inherited disorders. These approaches, while foundational, often lacked the specificity and sensitivity needed for presymptomatic diagnosis, carrier detection, and precise molecular characterization. The progression from Mendel's laws of inheritance to contemporary next-generation sequencing has fundamentally redefined how we identify, classify, and manage genetic diseases across all medical specialties.

1953 • Watson & Crick Double Helix

Elucidation of the DNA double helix structure provided the physical framework upon which all genetic diagnostics would eventually be built, establishing that heritable information is encoded in nucleotide sequences.

1977 • Sanger Sequencing Developed

Frederick Sanger's chain-termination method enabled reading DNA sequences base by base, opening the door to identifying point mutations and other small-scale genetic alterations in clinical specimens.

1985 • PCR Invented by Kary Mullis

The polymerase chain reaction revolutionized molecular diagnostics by enabling rapid amplification of specific DNA segments from minuscule samples, making genetic testing practical in clinical laboratories.

2003 • Human Genome Project Completed

The complete sequencing of the human genome provided a reference map for identifying disease-associated variants, catalyzing the development of targeted genetic tests and pharmacogenomic panels.

2010s • Clinical NGS & Precision Medicine

Next-generation sequencing platforms reduced costs and turnaround times dramatically, enabling whole-exome and whole-genome sequencing to enter routine clinical use for rare disease diagnosis and oncology.

These milestones collectively raise a central question for the clinician: given the expanding repertoire of genetic testing modalities, how does one select the appropriate test for a specific clinical scenario, interpret its results in the context of pretest probability, and communicate findings to patients in a meaningful way? Mastering these principles is essential not only for the USMLE but for the practice of evidence-based medicine in an era of precision medicine.

SECTION 2

Core Principles & Definitions

Genetic testing encompasses a broad array of laboratory techniques designed to detect alterations in chromosomes, genes, or proteins that are associated with disease. Understanding the fundamental principles underlying these tests requires familiarity with the types of genetic variation, the clinical contexts in which testing is performed, and the statistical parameters that govern test interpretation. The following core concepts form the foundation upon which all genetic diagnostic reasoning is built.

Analytical Validity

The ability of a test to accurately and reliably detect the specific genetic variant it is designed to identify. This addresses the question: does the assay measure what it claims to measure, with acceptable sensitivity and specificity at the molecular level?

Clinical Validity

The strength of the association between the detected genetic variant and the clinical phenotype or disease. A test may be analytically valid yet clinically meaningless if the variant has no proven disease association or exhibits incomplete penetrance.

Clinical Utility

Whether identifying the genetic variant leads to improved patient outcomes through changes in management, surveillance, or treatment. This is the highest bar and determines whether a test should be incorporated into clinical practice guidelines.

Penetrance & Expressivity

Penetrance refers to the proportion of individuals with a pathogenic variant who manifest the disease phenotype. Variable expressivity describes the range of clinical severity among those who are affected, complicating genotype-phenotype correlations.

Variant Classification

The ACMG/AMP framework classifies variants as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign. This five-tier system standardizes reporting and guides clinical decision-making.

✦

KEY TAKEAWAY

Think of genetic testing like a diagnostic imaging study: analytical validity is analogous to image resolution (can you see the structure clearly?), clinical validity is whether that finding correlates with disease (does a bright spot mean cancer?), and clinical utility is whether acting on the finding changes the patient's outcome (does knowing change what you do?). A test must pass all three hurdles to be clinically meaningful.

SECTION 3

Visual Overview of Genetic Testing Modalities

This diagram illustrates the major genetic testing modalities arranged by resolution, from chromosome-level karyotyping (~5 Mb) to single-nucleotide resolution achieved by next-generation sequencing. FISH bridges the gap between karyotyping and microarray by targeting specific loci with fluorescent probes. PCR-based assays and Southern blotting provide targeted approaches for known variants and repeat expansions, respectively.

The choice of genetic testing modality is fundamentally guided by the clinical question being asked. When a clinician suspects a whole-chromosome abnormality such as trisomy 21, a standard karyotype provides sufficient resolution. Conversely, a child with intellectual disability and dysmorphic features without an obvious chromosomal etiology warrants a chromosomal microarray to detect submicroscopic copy number variants. When a specific single-gene disorder like cystic fibrosis is suspected based on clinical presentation and ethnic background, targeted PCR-based mutation panels or Sanger sequencing of the CFTR gene may be the first-line approach. For diagnostically challenging cases involving phenotypic heterogeneity, whole-exome sequencing (WES) or whole-genome sequencing (WGS) offers the broadest unbiased interrogation of the coding or entire genome, respectively.

SECTION 4

Mechanisms & Technical Principles

Polymerase Chain Reaction (PCR)

PCR is the workhorse of molecular genetics. It exploits the thermostable DNA polymerase Taq to amplify a target DNA sequence exponentially through repeated cycles of denaturation (~95 °C), annealing (~55–65 °C), and extension (~72 °C). After n cycles, the number of copies of the target sequence increases approximately as 2ⁿ. This exponential amplification is what enables detection of DNA from a single cell, making PCR indispensable for prenatal testing, forensics, and infectious disease diagnostics. Variants of PCR include RT-PCR (for RNA targets via reverse transcription), quantitative PCR (qPCR) for real-time quantification, and allele-specific PCR for genotyping known variants such as sickle cell disease.

PCR AMPLIFICATION

N = N₀ × 2ⁿ

Where N = final number of DNA copies, N₀ = initial number of template molecules, and n = number of amplification cycles. After 30 cycles, a single template molecule yields approximately 10⁹ copies.

Fluorescence In Situ Hybridization (FISH)

FISH utilizes fluorescently labeled DNA probes that hybridize to complementary sequences on chromosomes, allowing visualization under fluorescence microscopy. The major probe types include centromeric probes (for chromosome enumeration in interphase nuclei, useful in rapid prenatal aneuploidy screening), locus-specific probes (for detecting microdeletions such as 22q11.2 in DiGeorge syndrome), and whole-chromosome paints (for identifying translocations). A key advantage of FISH is that it can be performed on non-dividing (interphase) cells, unlike conventional karyotyping which requires actively dividing metaphase cells. However, FISH is inherently targeted; the clinician must have a specific hypothesis about which locus to probe.

Next-Generation Sequencing (NGS)

NGS platforms perform massively parallel sequencing, generating millions of short reads simultaneously. In whole-exome sequencing (WES), hybridization capture probes enrich for the ~1.5% of the genome that encodes proteins (~22,000 genes), which harbors approximately 85% of known disease-causing mutations. Whole-genome sequencing (WGS) sequences the entire genome including non-coding regulatory regions, intronic sequences, and structural variants. Reads are aligned to a reference genome, and variant calling algorithms identify deviations from the reference sequence. The clinical interpretation pipeline then filters variants by population frequency, predicted functional impact, and disease association databases such as ClinVar and OMIM.

Chromosomal Microarray Analysis (CMA)

Chromosomal microarray is recommended by the American College of Medical Genetics as the first-tier test for evaluating patients with intellectual disability, developmental delay, autism spectrum disorder, and multiple congenital anomalies. Two major platforms exist: array comparative genomic hybridization (aCGH), which compares patient DNA to reference DNA to detect copy number variants (CNVs), and SNP arrays, which additionally detect uniparental disomy (UPD) and regions of homozygosity suggestive of consanguinity. CMA cannot detect balanced translocations or low-level mosaicism below ~20%, important limitations to remember for board examinations.

SECTION 5

Clinical Applications & Classification of Genetic Tests

Genetic tests are classified not only by their underlying technology but also by their clinical context. Understanding the purpose of a genetic test determines the appropriate methodology, the interpretation framework, and the counseling that must accompany results. The major categories of clinical genetic testing include diagnostic testing, carrier testing, prenatal testing, newborn screening, presymptomatic/predictive testing, and pharmacogenomic testing.

Clinical contexts of genetic testing span from symptomatic diagnostic evaluation to population-based newborn screening. Note the distinction between screening tests (high sensitivity, designed to identify at-risk individuals) and diagnostic tests (high specificity, designed to confirm or exclude disease). Pharmacogenomic and tumor profiling represent rapidly expanding applications of genetic testing in precision therapeutics.

Test Category	Target Population	Common Methods	Key Considerations
Newborn Screening	All neonates (mandatory in most states)	Tandem mass spectrometry, immunoreactive trypsinogen (IRT), TSH assay	Screens for treatable conditions; positive results require confirmatory testing
Prenatal Screening	Pregnant women, typically first/second trimester	Cell-free DNA (cfDNA/NIPT), quad screen, nuchal translucency	Non-invasive; cfDNA has high sensitivity for trisomies 21, 18, 13 but is a screening test
Prenatal Diagnostic	High-risk pregnancies after positive screening	Amniocentesis (15–20 wk), CVS (10–13 wk) with karyotype, FISH, or CMA	Invasive; small risk of miscarriage (~0.1–0.3%); definitive diagnosis
Carrier Testing	Reproductive-age adults, often ethnicity-based	Targeted mutation panels, expanded carrier screening (ECS)	For autosomal recessive and X-linked disorders; informs reproductive decisions
Pharmacogenomic	Patients starting medications with pharmacogenomic implications	SNP genotyping panels (e.g., CYP2C19, CYP2D6, TPMT, HLA-B*57:01)	Guides drug selection and dosing; prevents adverse drug reactions (e.g., abacavir hypersensitivity)

Summary of major genetic test categories and their clinical contexts

SECTION 6

Worked Example: Selecting & Interpreting a Genetic Test

The following clinical vignette demonstrates the reasoning process a clinician uses to select an appropriate genetic test, interpret the result, and integrate it with other clinical data. This type of stepwise clinical reasoning is frequently tested on the USMLE.

Clinical Vignette: Suspected Microdeletion Syndrome

1
Step 1 — Identify the Clinical Scenario

A 3-day-old neonate presents with tetralogy of Fallot, a cleft palate, and hypocalcemia. The neonatologist suspects DiGeorge syndrome (22q11.2 deletion syndrome). The family history is unremarkable. You are asked to recommend the most appropriate initial genetic test.
2
Step 2 — Determine the Type of Genetic Alteration

DiGeorge syndrome is caused by a microdeletion on chromosome 22q11.2, typically spanning 1.5–3 Mb. This is below the resolution of standard karyotyping (~5 Mb) but well within the resolution of FISH and CMA.

Suspected alteration: submicroscopic deletion (~1.5–3 Mb)
3
Step 3 — Select the Appropriate Test

When the clinical phenotype strongly suggests a specific microdeletion syndrome, FISH with a 22q11.2-specific probe is the rapid, targeted first-line test. It provides results within 24–48 hours. Alternatively, chromosomal microarray (CMA) would not only detect the 22q11.2 deletion but also identify any additional CNVs that might contribute to the phenotype, though turnaround time is typically 2–4 weeks.

Best initial test: FISH for 22q11.2 (rapid, targeted, high sensitivity)
4
Step 4 — Interpret the Result

The FISH result shows a single signal for the 22q11.2 probe on one chromosome 22 and the expected two signals for a control probe, confirming a hemizygous deletion at 22q11.2. This is consistent with the clinical diagnosis of DiGeorge syndrome. Approximately 93% of cases arise de novo, but parental FISH testing is recommended to assess recurrence risk.

Diagnosis confirmed: 22q11.2 deletion syndrome (DiGeorge syndrome)
5
Step 5 — Clinical Implications

The confirmed diagnosis triggers a comprehensive multisystem evaluation including echocardiography, calcium and parathyroid hormone levels, immunologic assessment (T-cell subsets), renal ultrasound, and developmental surveillance. Genetic counseling is provided to the family regarding the typically de novo nature of the deletion, the 50% recurrence risk if a parent carries the deletion, and the wide phenotypic variability even among family members with the same deletion.

SECTION 7

Strengths & Limitations of Major Testing Modalities

No single genetic test is universally superior; each modality has specific strengths and limitations that must be weighed against the clinical question at hand. The USMLE frequently tests the ability to recognize which test is most appropriate for a given clinical scenario, as well as the limitations that may produce false-negative results.

Modality	Strengths	Limitations
Karyotype	Detects aneuploidies, balanced translocations, large deletions/duplications, inversions; provides whole-genome overview at chromosomal level	Low resolution (~5 Mb); requires dividing cells; slow turnaround (1–2 weeks); cannot detect submicroscopic changes
FISH	Rapid (24–48 hrs); works on interphase cells; highly sensitive for targeted loci; can detect microdeletions and gene fusions	Targeted only (must know what to look for); limited number of probes per assay; cannot provide genome-wide information
CMA	Genome-wide CNV detection; higher resolution than karyotype; SNP arrays detect UPD and consanguinity; no cell culture needed	Cannot detect balanced rearrangements or low-level mosaicism (<20%); frequent VUS in CNVs; does not detect point mutations
Sanger Sequencing	Gold standard for confirming point mutations; high accuracy for single-gene analysis; well-established and widely available	Examines only one gene/exon at a time; expensive for multigene panels; cannot detect CNVs or structural variants
NGS (WES/WGS)	Massive throughput; detects SNVs, indels, some CNVs; unbiased approach for genetically heterogeneous conditions; decreasing cost	High VUS rate; may miss trinucleotide repeats and balanced translocations; requires bioinformatics infrastructure; incidental findings
Southern Blot	Detects large trinucleotide repeat expansions (e.g., Fragile X full mutations >200 CGG repeats); can assess methylation status	Labor-intensive; slow (days to weeks); requires large DNA quantities; largely replaced by PCR/NGS for most applications

Comparison of major genetic testing modalities

⚡

HIGH-YIELD BOARD PEARL

When a USMLE question asks about a child with intellectual disability and a normal karyotype, the next best test is chromosomal microarray (CMA). If the question involves a boy with intellectual disability, macro-orchidism, and a long face, think Fragile X syndrome — the test of choice is PCR for FMR1 CGG repeat number (with Southern blot for full mutations). Remember: CMA cannot detect balanced translocations, trinucleotide repeat disorders, or point mutations — these are the most commonly tested limitations.

SECTION 8

Emerging Frontiers & Ethical Considerations

The rapid advancement of sequencing technology and bioinformatics has propelled genetic testing beyond traditional single-gene and chromosomal analyses into an era of comprehensive genomic medicine. Understanding how current testing compares to emerging approaches is important for contextualizing the trajectory of genetic diagnostics, and these concepts increasingly appear on board examinations.

Established Approach	Emerging Approach	Key Advancement
Targeted gene panels (10–100 genes)	Whole-exome/genome sequencing as first-tier test	Unbiased approach detects unexpected diagnoses; reduces diagnostic odyssey for rare diseases
Maternal serum screening (quad screen)	Cell-free DNA (cfDNA/NIPT) for all pregnancies	Higher sensitivity and specificity for common trisomies; expanding to microdeletions and single-gene disorders
Single-gene pharmacogenomic tests	Preemptive multi-gene pharmacogenomic panels	Results available before drug prescribing; integrated into EHR with clinical decision support
Tumor tissue biopsy for somatic mutations	Liquid biopsy (circulating tumor DNA)	Non-invasive monitoring of treatment response; detects resistance mutations; serial sampling feasible

Established vs. emerging genetic testing approaches

Ethical, Legal, and Social Implications (ELSI)

The expansion of genetic testing raises critical ethical considerations that are increasingly tested on the USMLE. The Genetic Information Nondiscrimination Act (GINA) prohibits discrimination by health insurers and employers based on genetic information, but notably does not cover life insurance, disability insurance, or long-term care insurance. Informed consent for genetic testing must address the possibility of incidental (secondary) findings — variants in genes unrelated to the indication for testing that have medical actionability. The ACMG currently recommends reporting pathogenic variants in a defined list of ~78 genes associated with highly penetrant, medically actionable conditions regardless of the original indication for sequencing. Variants of uncertain significance (VUS) present a unique counseling challenge: they should not be used for clinical decision-making but can cause significant patient anxiety and may be reclassified over time as more data accumulates.

⚠

USMLE Ethical Pearl

When a patient undergoes whole-exome sequencing and an incidental finding of a BRCA1 pathogenic variant is discovered, the appropriate response is to disclose the finding (per ACMG recommendations), offer genetic counseling, and discuss implications for cancer surveillance. The patient has the right to decline learning about secondary findings; this preference should be established during the informed consent process before testing is performed.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A couple with no family history of genetic disease asks about carrier screening before conception. They are both of Ashkenazi Jewish descent. The physician orders an expanded carrier screening panel that returns negative for all tested conditions. The couple asks whether this guarantees their children will be unaffected. What is the most accurate counseling response, and what concept explains why negative carrier screening does not eliminate risk?

Show answer

A negative carrier screening result significantly reduces but does not eliminate the risk of having an affected child. The concept of residual risk explains this: carrier screening panels test for the most common known pathogenic variants but cannot detect all possible mutations in a given gene. Novel, rare, or private mutations that are not included in the panel would be missed, leaving a small residual carrier risk. Additionally, de novo mutations can occur regardless of parental carrier status. The residual risk varies by gene, ethnicity, and the comprehensiveness of the panel, and should be quantified using Bayesian analysis when available.

Question 2: BASIC CALCULATION

A PCR reaction begins with 10 copies of a target DNA sequence. After 25 cycles of amplification, approximately how many copies of the target sequence are present? Use the formula N = N₀ × 2ⁿ. Express your answer in scientific notation.

Show answer

Using the PCR amplification formula: N = N₀ × 2ⁿ = 10 × 2²⁵. Since 2¹⁰ ≈ 1,024 ≈ 10³, we can estimate 2²⁵ = 2¹⁰ × 2¹⁰ × 2⁵ ≈ 10³ × 10³ × 32 = 3.2 × 10⁷. Therefore, N = 10 × 3.2 × 10⁷ ≈ 3.36 × 10⁸ copies (the exact value is 10 × 33,554,432 = 335,544,320). This exponential amplification is what makes PCR exquisitely sensitive, capable of detecting DNA from a single cell in clinical specimens. In practice, amplification efficiency is less than 100%, so the actual yield is somewhat lower than this theoretical maximum.

Question 3: INTERMEDIATE

A 2-year-old boy presents with global developmental delay, autism spectrum features, and no dysmorphic features. Karyotype is normal (46,XY). Fragile X testing (FMR1 CGG repeat analysis) shows a normal repeat number. What is the most appropriate next step in the genetic evaluation, and why is this test preferred over alternative modalities in this clinical context?

Show answer

The most appropriate next test is chromosomal microarray analysis (CMA). According to ACMG guidelines, CMA is the first-tier test for children with intellectual disability, developmental delay, or autism spectrum disorder. In this case, the normal karyotype rules out large chromosomal abnormalities, and normal Fragile X testing excludes FMR1 repeat expansion. CMA can detect submicroscopic copy number variants (microdeletions and microduplications) that are below the resolution of karyotyping and account for 15–20% of cases of unexplained intellectual disability. CMA is preferred over whole-exome sequencing at this stage because it has a higher diagnostic yield for CNVs, is less expensive, generates fewer variants of uncertain significance, and has a well-established evidence base for this indication. If CMA is also non-diagnostic, whole-exome sequencing would be the subsequent step.

Question 4: APPLIED

A 32-year-old pregnant woman at 12 weeks gestation undergoes cell-free DNA (cfDNA) screening, which returns a high-risk result for trisomy 21. The patient asks whether she should begin preparing for a child with Down syndrome. Her obstetrician explains that confirmatory testing is needed. What is the positive predictive value (PPV) of cfDNA for trisomy 21 in a 32-year-old woman, and why does the PPV differ from the test's quoted sensitivity of ~99%? What confirmatory test should be recommended?

Show answer

The sensitivity of cfDNA for trisomy 21 is approximately 99%, and specificity is approximately 99.9%. However, positive predictive value (PPV) is critically influenced by the prevalence of the condition in the tested population. For a 32-year-old woman, the a priori risk of trisomy 21 is approximately 1 in 700. Using Bayesian reasoning, the PPV in this age group is approximately 50–80%, meaning that 20–50% of positive cfDNA results are false positives (primarily due to confined placental mosaicism, maternal copy number variants, or vanishing twin). This illustrates why cfDNA is a screening test, not a diagnostic test. The appropriate confirmatory test is amniocentesis with karyotype or CMA, which analyzes fetal cells directly and provides a definitive diagnosis. The patient should be counseled that a positive cfDNA result raises the probability of trisomy 21 but does not confirm it.

Question 5: CRITICAL THINKING

A 28-year-old woman with a strong family history of breast and ovarian cancer undergoes BRCA1/BRCA2 sequencing, which reveals a variant of uncertain significance (VUS) in BRCA2. She asks whether she should undergo prophylactic bilateral mastectomy based on this result. Discuss the appropriate clinical approach to a VUS result, the principles that govern variant reclassification, and how you would counsel this patient regarding risk management while the significance of the variant remains uncertain.

Show answer

A variant of uncertain significance (VUS) should NOT be used to guide clinical management, including surgical decisions like prophylactic mastectomy. The ACMG/AMP five-tier classification system categorizes VUS as variants for which there is insufficient evidence to determine pathogenicity. The clinical approach involves several components: (1) Manage the patient based on her family history alone, not the VUS — her strong family history independently warrants enhanced surveillance with annual breast MRI and mammography beginning at age 25; (2) Consider co-segregation analysis — testing affected family members to determine whether the VUS tracks with cancer in the family; (3) Encourage periodic reclassification review, as VUS are frequently reclassified (most commonly to benign/likely benign) as population databases grow and functional studies are performed; (4) Explain that computational predictions, population frequency data, and functional assays all contribute to eventual reclassification. The patient should be reassured that her management plan based on family history provides appropriate risk reduction while the variant undergoes ongoing evaluation.

SUMMARY

Lesson Summary

Summary

Genetic testing encompasses a spectrum of laboratory techniques ranging from karyotyping (chromosome-level, ~5 Mb resolution) through FISH (locus-specific, ~100 kb) and chromosomal microarray (genome-wide CNV, ~50–100 kb) to next-generation sequencing (single-nucleotide resolution). Each modality has defined strengths and limitations: karyotyping uniquely detects balanced translocations, CMA is the first-tier test for unexplained intellectual disability but cannot detect balanced rearrangements or point mutations, and NGS offers unbiased genome-wide analysis but generates frequent variants of uncertain significance (VUS). PCR remains the backbone of targeted molecular diagnostics with its exponential amplification (N = N₀ × 2ⁿ), while Southern blotting retains a niche role for large trinucleotide repeat disorders like Fragile X syndrome.

Clinical application requires understanding the distinction between screening tests (e.g., cfDNA/NIPT, newborn screening) and diagnostic tests (e.g., amniocentesis with karyotype), recognizing that positive predictive value depends heavily on disease prevalence. The ACMG/AMP variant classification system (pathogenic → likely pathogenic → VUS → likely benign → benign) standardizes reporting, and VUS should never drive clinical management. Ethical principles including informed consent, the GINA Act, management of incidental findings, and pharmacogenomic testing for drug safety are high-yield topics for the USMLE that integrate genetics with medical ethics and clinical reasoning.